HYDROXYCHLOROQUINE SULFATE 200mg. IP

A potent antimalarial agent that has an established role in the management of autoimmune rheumatic diseases. (Alina Casian, 2018) An antimalarial drug that is also used as a second-line treatment of rheumatoid arthritis. (Samantha J Carmichael, 2003) Has immunomodulatory, hypolipidemic, hypoglycemic, antithrombotic properties and diminishes the risk of malignancies. (Álvaro Danza, 2016) An efficacious drug in the treatment of autoimmune diseases, including systemic lupus erythematosus, discoid lupus erythematosus, and rheumatoid arthritis. (Crispin Abarientos, 2011) Effective and safe therapy for systemic lupus erythematosus, mild-moderate rheumatoid arthritis, and Sjogren's syndrome. (K D Rainsford, 2015) Demonstrates a significant and multifaceted benefit in patients with systemic lupus erythematosus. (Eugen Alexander Shippey, 2018) A valuable agent in the treatment of oral lichen planus. (Eisen, 1993) Exhibits low incidences of gastrointestinal adverse reactions compared with chloroquine in the treatment of systemic lupus erythematosus, rheumatoid arthritis. (K D Rainsford, 2015) Reduces atherosclerosis and risks of cardiovascular disease in rheumatic patients. (K D Rainsford, 2015) Improves glycemia and reduces the risks of type II diabetes mellitus. (K D Rainsford, 2015) Ameliorates the dermatological manifestations in Dermatomyositis and has a positive effect on Sarcoidosis treatment. (Álvaro Danza D. G.-I., 2016) A potentially valuable treatment for patients with systemic vasculitis who are at risk of infections, malignancy, and thrombotic events. (Alina Casian, 2018) Displays a trend of lower disease activity and fewer incidences of flares in systemic lupus erythematosus patients. (Chi Chiu Mok, 2016)